Last reviewed · How we verify
Matching Placebo to Ustekinumab
Matching Placebo to Ustekinumab is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 3 development.
This is a placebo formulation designed to match the appearance and administration route of ustekinumab for blinded clinical trial comparison.
At a glance
| Generic name | Matching Placebo to Ustekinumab |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Matching placebo serves as a control in phase 3 trials to evaluate the efficacy and safety of ustekinumab, an IL-12/IL-23 inhibitor. The placebo is formulated to be indistinguishable from the active drug in terms of appearance, taste, and injection characteristics, enabling proper blinding of study participants and investigators. This allows for accurate assessment of ustekinumab's true therapeutic benefit independent of placebo effect.
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (PHASE3)
- A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (PHASE2)
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (PHASE3)
- A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus (PHASE3)
- A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching Placebo to Ustekinumab CI brief — competitive landscape report
- Matching Placebo to Ustekinumab updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI